CTOs on the Move

Precision Health Media

www.precisionhealthmedia.com

 
New York-based Precision Health Media (formerly Good Health Media) delivers specific health condition audiences to pharma and consumer brands.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Hamilton

The leader in liquid handling equipment and laboratory automation technology, Hamilton Robotics is recognized for advancing life science and biotechnology industries with products that offer reliability, performance and flexibility. Hamilton is the ind...

Clinical Trials Services

Clinical Trials Services is a Lancaster, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RenovoRx

RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via our proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP®) therapy platform. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. Our lead product candidate, RenovoGem, is a combination of gemcitabine and our patented delivery system regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). Targeted therapy via RenovoTAMP platform safely and without transmission to non-targeted areas, is our primary focus. RenovoRx`s patent portfolio currently includes seven issued US patents and one European patent for ourtechnology with several additional patents pending in the US, Europe, and Asia. After demonstrating a median survival of 27.9 months in Phase 1/2 clinical trials vs. 12-15 months reported in historical studies for this patient population, RenovoRx secured two separate Orphan Drug Designations from the FDA for intra-arterial gemcitabine: pancreatic cancer and bile duct cancer (cholangiocarcinoma). This therapy is being further studied in the currently enrolling Phase 3 TIGeR-PaC clinical trial in pancreatic cancer and has a primary endpoint of overall survival and several secondary endpoints, including quality of life. The Phase 3 TIGeR-PaC clinical trial is enrolling unresectable locally advanced pancreatic cancer patients (LAPC) in the United States.

Isoflex

Isoflex is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AnGes Inc

AnGes Inc is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.